Educo Life Sciences Launches New AI for Drug Development & Pharma Strategy Training Course

New practical training programme helps pharmaceutical and biotech professionals harness Artificial Intelligence across drug discovery, clinical development and strategic decision-making.

Educo Life Sciences has announced the launch of its new AI for Drug Development & Pharma Strategy training course, designed to help pharmaceutical and biotechnology professionals confidently apply Artificial Intelligence (AI) throughout the drug development lifecycle.

As AI rapidly transforms the life sciences industry, organisations are under increasing pressure to understand where AI delivers genuine value and how it can be implemented responsibly. Industry investment in AI continues to grow as companies seek to accelerate research, improve clinical development, enhance due diligence and make better strategic decisions.

The new two-day live online programme moves beyond theory, focusing on practical applications that professionals can immediately implement within their own organisations. Participants will explore how AI can support target identification, molecule generation, clinical trial optimisation, competitive intelligence, due diligence, regulatory strategy and portfolio decision-making using real-world pharmaceutical examples and interactive exercises.

Unlike many AI courses aimed at data scientists or software developers, Educo's programme has been specifically developed for professionals working across pharmaceutical and biotech organisations, including R&D, clinical development, regulatory affairs, business development, licensing, commercial strategy and digital transformation.

The course also addresses many of the emerging technologies now shaping the future of AI in life sciences, including Large Language Models (LLMs), Agentic AI, APIs, Model Context Protocols (MCPs), knowledge graphs and AI governance, giving delegates the confidence to understand both today's capabilities and tomorrow's opportunities.

"Artificial Intelligence is no longer a future technology—it is becoming a core capability across the pharmaceutical industry," said Alexander Pearce, Director of Marketing & Business Development at Educo Life Sciences.

"Many professionals understand that AI will change the way medicines are discovered and developed, but they're unsure where to start or how to apply it effectively in their own role. We created this course to bridge that gap, providing practical knowledge, real pharmaceutical examples and hands-on techniques that delegates can immediately take back into their organisations."

The programme is led by an experienced industry expert and combines strategic insight with practical demonstrations of AI tools currently being used across drug discovery, clinical development, due diligence and pharmaceutical strategy.

To support professionals beginning their AI journey, Educo is also offering a free introductory 60-minute online module covering AI fundamentals, Large Language Models and practical considerations when adopting AI within pharmaceutical organisations. The session is delivered live and recorded, allowing delegates to access the content on demand before deciding whether to enrol on the full course.

The course forms part of Educo Life Sciences' growing portfolio of AI training programmes developed specifically for pharmaceutical, biotechnology and medical device professionals as demand for AI skills continues to accelerate across the sector.

The first live delivery of AI for Drug Development & Pharma Strategy takes place on 28–29 October 2026.

About Educo Life Sciences

Educo Life Sciences is a specialist provider of technical training for the pharmaceutical, biotechnology, cell and gene therapy, and medical device industries. Through live online, classroom, hybrid and on-demand learning, Educo helps professionals develop the knowledge, skills and confidence required to navigate an increasingly complex life sciences landscape. Its portfolio covers regulatory affairs, CMC, manufacturing, quality, clinical development, medical devices and emerging technologies including Artificial Intelligence.